![Frontiers | Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease Frontiers | Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease](https://www.frontiersin.org/files/Articles/493301/fphar-11-00146-HTML/image_m/fphar-11-00146-g001.jpg)
Frontiers | Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/08339483-5351-49f4-9caf-45ba5014d108/15ff1b.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate](https://i1.rgstatic.net/ii/profile.image/375942640881665-1466643118917_Q512/Hannah-Kirkwood-2.jpg)
How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/0f7b0cea-8b0f-4c9a-bebf-7c70c3d1d072/15ff1a.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press](https://nap.nationalacademies.org/books/0309089964/gifmid/145.gif)
References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press
![PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial](https://i1.rgstatic.net/publication/335550663_Ticagrelor_in_patients_with_diabetes_and_stable_coronary_artery_disease_with_a_history_of_previous_percutaneous_coronary_intervention_THEMIS-PCI_a_phase_3_placebo-controlled_randomised_trial/links/5dab261aa6fdccc99d91d5b6/largepreview.png)